Trial Profile

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary)
Indications Hodgkin's disease
Focus Therapeutic Use
Acronyms TIRHOL
Sponsors BeiGene

Most Recent Events

16 Oct 2024 Status changed from active, no longer recruiting to completed.
12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, study follow-up is ongoing, but durable responses have been observed, especially in patients achieving CR.
12 Dec 2023 Primary endpoint has been met. (Overall Response Rate (ORR)) , according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com